Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05948358
Other study ID # Menstrual Distress
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 1, 2023
Est. completion date November 30, 2023

Study information

Verified date July 2023
Source Karabuk University
Contact Nurcan Contarli, MSc
Phone 03704189396
Email nurcancontarli@karabuk.edu.tr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Menstruation is a process in which metabolic and hormonal changes occur periodically every month to maintain reproductive functions in women. This cycle, which continues from menarche to menopause, repeats approximately every 28 days and lasts 3-7 days (1). The menstrual cycle is divided into three phases, the follicular phase, the ovulation phase, and the luteal phase, in which the levels of estrogen and progesterone hormones change (2,3). In this cycle, which is regulated by the hormones released from the pituitary, hypothalamus and ovary, changes occur not only in the genital organs, but also in the nervous system, cardiovascular system, respiratory system, musculoskeletal system and metabolic functions (4). Responses to these changes, which cause physiological stress in the organism in women, are perceived in different degrees. The presence of recurrent abnormal bleeding or excessive pain may be a sign of various menstrual disorders (5). Evaluation of menstrual problems that negatively affect women's mood, social and work life is clinically important (6,7). The scale, called Menstrual Distress Questionnaire (MEDI-Q), was developed by Vannuccini et al. (2021), it is a tool that comprehensively evaluates menstrual problems (8). MEDI-Q assesses the effects of menstrual symptoms on quality of life, recreational activities, work and social relationships. It consists of 25 items covering different areas of menstruation-related symptoms such as pain, discomfort, psychological and cognitive changes, and gastrointestinal disturbances. The level of distress caused by each symptom is assessed in the menstrual cycle phases, taking into account not only its impact on functionality and quality of life, but also its frequency. MEDI-Q is a scale with good test-retest reliability and internal consistency (Cronbach's = 0.85) (8,9). The scale provides a total score (MEDI-Q Total Score) and three subscales that assess general menstrual distress. Subscales; the number of distressing symptoms (MS) during menstruation, the mean level of distress related to menstrual symptoms (MSD), and the Menstrual Specificity Index (MESI) (8,9), which measures the proportion of symptoms at which distress exacerbates during the menstrual phase.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 300
Est. completion date November 30, 2023
Est. primary completion date October 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Female gender - 18-35 years old - Volunteer - Native speaker Turkish Exclusion Criteria: - Pregnancy or breastfeeding - Having a mental health problem

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Menstrual Distress Questionnaire
The Menstrual Distress Questionnaire (MEDI-Q) is a new tool originally developed in Italian that comprehensively evaluates menstrual-related distress.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Karabuk University

Outcome

Type Measure Description Time frame Safety issue
Primary The Menstrual Distress Questionnaire (MEDI-Q) The Menstrual Distress Questionnaire (MEDI-Q) is a new tool originally developed in Italian that comprehensively evaluates menstrual-related distress. 10 minutes
See also
  Status Clinical Trial Phase
Completed NCT00195559 - Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder Phase 3
Terminated NCT01183377 - Frequency of Female Athlete Triad Among Elite Female Athlete of Iran in Different Sport in 2007 N/A
Not yet recruiting NCT04583943 - Lifestyle Influence on Primary Dysmenorrhea
Completed NCT05928650 - Comparison of Menstrual Function Among Sprinters, Long Marathon Runners, and Non-Athletic Females
Completed NCT04938622 - Bioenergetics of Exercise-Induced Menstrual Disturbances N/A
Completed NCT05107804 - Energy Restriction and Hormones in Premenopausal Women N/A
Recruiting NCT06297980 - Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes N/A
Completed NCT02070692 - Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users Phase 4
Active, not recruiting NCT01103518 - Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation Phase 4
Completed NCT00128934 - Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder Phase 3
Completed NCT00001259 - A Treatment Study for Premenstrual Syndrome (PMS) Phase 1
Completed NCT02486757 - Investigation of Female Reproductive Hormone Dynamics During Adolescence Early Phase 1
Withdrawn NCT00357981 - Continuous Use of the Contraceptive Patch and the Personal Economic Impact. N/A